两种补肾方药对骨质疏松症患者骨密度及疼痛评分影响的Meta分析

A meta-analysis of efficacy of two kinds of the Bushen medicine on BMD and VAS in osteoporosis patients

目的:系统评价并对比以金匮肾气丸为主的补肾方药与以六味地黄丸为主的补肾方药在治疗骨质疏松症的临床疗效。方法:计算机检索SCI、PubMed、中国期刊全文数据库(CNKI)、Cochrane图书馆、EMbase、万方等各类中、英文数据库,检索年限截止至2019年3月,检索有关补肾方药治疗骨质疏松症的随机对照文献(Randomized Controlled Trial,RCTs)。采用RevMan 5.3软件进行数据的Meta分析。结果:纳入5项RCT分为两组(一组2项,一组3项),涉及受试者421例,Meta分析结果显示,在骨密度(Bone Mineral Density,BMD)方面:以金匮肾气丸为主的补肾方药,治疗组优于对照组最为明显(MD=-2.13,95%CI为-3.00^-1.26,P<0.00001);在视觉模拟疼痛评分(Visual Analogue Scale,VAS)方面:以金匮肾气丸为主的补肾方药,治疗组优于对照组最为明显(MD=0.03,95%CI为-0.01~0.06,P=0.10)。结论:以金匮肾气丸为主的补肾方药在治疗骨质疏松症的临床疗效比以六味地黄丸为主的补肾方药积极意义更高。

Objective:To compare efficacy of Jingui Shenqi Wan(金匮肾气丸)and Liuwei Dihuang Wan(六味地黄丸)on osteoporosis.Methods:RCTs literature of treating osteoporosis with the Bushen medicine(补肾药)was searched from building-up period to March 2019 in SCI,PubMed,CNKI,the Cochrane library,EMbase,Wangfang Date.A Meta of the data was analyzed by RevMan 5.3 software.Results:5 RCT are divided into two groups(2 in a group,3 in another group),and 421 cases are involved.A Meta-analysis shows that efficacy of Jingui Shenqi Wan on BMD is better than Liuwei Dihuang Wan(MD=-2.13,95%,CI-3.00^-1.26,P<0.00001).Efficacy of Jinkui Shenqi Wan on VAS is better(MD=0.03,95%,CI 0.01~0.06,P=0.10).Conclusion:Jingui Shenqi Wan on osteoporosis is more effective.